Percutaneous coronary intervention has similar 5-year survival rates to coronary artery bypass grafting surgery for patients with unprotected left main artery disease

Affiliations

¹ Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Cardiology, Imperial College London, London, UK.

Comment

Carlos Collet et al. Evid Based Med. 2017 Aug.

. 2017 Aug;22(4):151-152.

doi: 10.1136/ebmed-2017-110682. Epub 2017 Jul 6.

¹ Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Cardiology, Imperial College London, London, UK.

No abstract available

Conflict of interest statement

Competing interests: PWS is a member of the international advisory board of Abbott Vascular.

Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
Mäkikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, Trovik T, Eskola M, Romppanen H, Kellerth T, Ravkilde J, Jensen LO, Kalinauskas G, Linder RB, Pentikainen M, Hervold A, Banning A, Zaman A, Cotton J, Eriksen E, Margus S, Sørensen HT, Nielsen PH, Niemelä M, Kervinen K, Lassen JF, Maeng M, Oldroyd K, Berg G, Walsh SJ, Hanratty CG, Kumsars I, Stradins P, Steigen TK, Fröbert O, Graham AN, Endresen PC, Corbascio M, Kajander O, Trivedi U, Hartikainen J, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH; NOBLE study investigators. Mäkikallio T, et al. Lancet. 2016 Dec 3;388(10061):2743-2752. doi: 10.1016/S0140-6736(16)32052-9. Epub 2016 Oct 31. Lancet. 2016. PMID: 27810312 Clinical Trial.